David A. Siegel Iovance Biotherapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 2,334,900 shares of IOVA stock, worth $5.23 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,334,900

Holding current value

$5.23 Million

% of portfolio

0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.66 - $3.61 $3.88 Million - $8.43 Million	2,334,900 New	2,334,900 $4.02 Million
Q2 2023 Aug 14, 2023	SELL	$5.36 - $9.06 $2.37 Million - $4 Million	-441,500 Reduced 35.48%	802,700 $5.65 Million
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $2.19 Million - $3.26 Million	396,800 Added 46.83%	1,244,200 $7.6 Million
Q4 2022 Feb 14, 2023	BUY	$5.62 - $10.0 $970,574 - $1.73 Million	172,700 Added 25.6%	847,400 $5.41 Million
Q3 2022 Nov 14, 2022	BUY	$9.53 - $13.11 $4.68 Million - $6.44 Million	491,600 Added 268.49%	674,700 $6.46 Million
Q2 2022 Aug 15, 2022	BUY	$6.38 - $18.33 $844,712 - $2.43 Million	132,400 Added 261.14%	183,100 $2.02 Million
Q1 2022 May 16, 2022	BUY	$12.38 - $19.1 $55,710 - $85,950	4,500 Added 9.74%	50,700 $844,000
Q4 2021 Feb 14, 2022	BUY	$16.55 - $27.63 $764,610 - $1.28 Million	46,200 New	46,200 $882,000
Q2 2021 Aug 16, 2021	SELL	$16.33 - $33.07 $1.69 Million - $3.41 Million	-103,200 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$28.67 - $52.59 $599,203 - $1.1 Million	-20,900 Reduced 16.84%	103,200 $3.27 Million
Q4 2020 Feb 16, 2021	BUY	$28.04 - $50.26 $2.21 Million - $3.97 Million	78,900 Added 174.56%	124,100 $5.76 Million
Q3 2020 Nov 16, 2020	BUY	$27.75 - $36.3 $208,125 - $272,250	7,500 Added 19.89%	45,200 $1.49 Million
Q2 2020 Aug 14, 2020	SELL	$27.21 - $41.0 $32,652 - $49,200	-1,200 Reduced 3.08%	37,700 $1.04 Million
Q1 2020 May 15, 2020	SELL	$19.54 - $38.85 $1.21 Million - $2.4 Million	-61,900 Reduced 61.41%	38,900 $1.16 Million
Q4 2019 Feb 14, 2020	BUY	$17.95 - $29.41 $1.32 Million - $2.16 Million	73,300 Added 266.55%	100,800 $2.79 Million
Q3 2019 Nov 14, 2019	BUY	$17.99 - $26.0 $494,724 - $715,000	27,500 New	27,500 $501,000
Q2 2019 Aug 14, 2019	SELL	$9.78 - $24.52 $502,691 - $1.26 Million	-51,400 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$8.41 - $11.26 $307,806 - $412,116	-36,600 Reduced 41.59%	51,400 $489,000
Q4 2018 Feb 14, 2019	BUY	$7.51 - $11.93 $660,880 - $1.05 Million	88,000 New	88,000 $779,000
Q3 2018 Nov 14, 2018	SELL	$11.25 - $17.7 $222,750 - $350,460	-19,800 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$12.45 - $16.95 $246,510 - $335,610	19,800 New	19,800 $253,000

Others Institutions Holding IOVA

# of Institutions

292

Shares Held

233M

Call Options Held

1.14M

Put Options Held

1.15M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $353M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account